Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 53 of 97, showing 5 Applications out of 482 total, starting on record 261, ending on 265

# Protocol No Study Title Investigator(s) & Site(s)

261.

ECCT/19/11/05   Point-of-care Urine Monitoring of Adherence (PUMA)
    Point-of-care Urine Monitoring of Adherence (PUMA): Testing a Real-Time Urine Assay of Tenofovir in PrEP   Pilot trial to examine the feasibility, acceptability and impact on longer-term adherence of an intervention using a new urine-based tenofovir adherence assay       
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR PHRD (THIKA) PROJECT
 
View

262.

ECCT/19/11/04   Second line switch to Dolutegravir (2SD) study
    Switching Treatment-Experienced, Integrase Inhibitor-Naïve, Virally Suppressed HIV-1 Infected Adults from Ritonavir boosted Protease Inhibitors to Dolutegravir: An Open-Label Randomized Controlled Trial               
Principal Investigator(s)
1. Loice Achieng
Site(s) in Kenya
1. Kenyatta National Hospital (Nairobi City county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
3. Thika Level 5 Hospital (Kiambu county)
4. Kiambu Level 5 Hospital (Kiambu county)
 
View

263.

ECCT/19/11/03   A Pilot BE study for Enalpril 5mg
    A bioequivalent pilot study of a locally-produced brand of enalapril tablets:  a key step towards implementation of bioequivalent study regulatory requirements in East Africa   
Principal Investigator(s)
1. Simon Njoroge Njenga
Site(s) in Kenya
Kenya Medical Research Institute
 
View

264.

ECCT/19/11/02   PrEP and dPEP
    PrEP and dPEP: Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxis   
Principal Investigator(s)
1. Dr.Elizabeth Bukusi Ann Bukusi
Site(s) in Kenya
KEMRI/CMR/RCTP Kisumu-Lumumba Sub-County Hospital
 
View

265.

ECCT/19/11/01   A study to determine if candidate malaria vaccines are safe, effective, and induce immunity among Kenyan adults.
    Safety, immunogenicity, and efficacy of R21/Matrix M (R21/MM) and ChAd63/MVA-ME-TRAP in the context of controlled human malaria infection: A Phase IIb Trial in Kenyan Adults.   
Principal Investigator(s)
1. Melissa Kapulu
Site(s) in Kenya
KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya.
 
View